Commentary · 29 Jan 2021
Conference abstractPublished 29 Jun 2017
Combinatorial chemo/immunotherapy for soft tissue sarcoma
Sarcoma Oncology Center, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Trabectedin has direct cytotoxic activity in tumor cells and has been shown to deplete pro-tumor macrophages in the tumor microenvironment. Nivolumab inhibits the immune checkpoint molecule, PD-1, which restores anti-tumor activity in tumorinfiltrating T cells. Purpose: To assess the safety/toxicity and efficacy of sequential administration of trabectedin and nivolumab in patients with advanced soft tissue sarcoma (STS). Methodology: 14 patients with metastatic STS were evaluated. Each patient received one dose of single-agent trabectedin (1.5 mg/ m2 continuous intravenous infusion, CIV, for 24 hours), followed by trabectedin CIV every 3 weeks, and nivolumab 3 mg/kg IV every 2 weeks. Safety/toxicity was analyzed using the NIH/NCI CTCAE v.4.03. Tumor responses were assessed by RECIST v1.1 and immune-related response criteria (irRECIST). Findings: Histologic subtypes include undifferentiated pleomorphic sarcoma, leiomyosarcoma, synovial sarcoma, myxoid liposarcoma and chondrosarcoma. All patients had metastatic disease and a median of 4 lines of prior chemotherapy. Safety Analysis: Grade 3 treatment emergent adverse events include anemia, fatigue, decreased platelet count, decreased granulocyte count and increased creatine kinase. Efficacy Analysis: 13 patients received at least 2 cycles of sequential chemo-/immuno-therapy, had follow-up CT scan/MRI, and were evaluated for objective response (OR), best overall response rate (BORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). There were 3 partial responses, 7 stable disease and 3 progressive disease, with BORR of 23.1%, DCR of 76.9%, median PFS >7.8 months (range: 3.5->10.4 months), median OS >8.4 months (3.6->10.4 months), 6 month PFS rate, 69.2%, and 6 month OS rate, 92%. Six-month OS rate for all 14 patients was 86%. In a phase 3 study, the median PFS was 4.2 months using trabectedin alone. Conclusion: Taken together, the data suggest that paired administration of trabectedin and nivolumab is safe, and that this chemo-/ immuno-therapy approach has synergistic activity.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 18 Dec 2017
Advanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab.
Review article · 2018
With the Tsunami of Immunotherapy, Will Soft Tissue Sarcoma Remain an Immune Desert?
Commentary · 2017
Purity of Transferred CD8+ T cells is Crucial for Safety and Efficacy of Combinatorial Tumor Immunotherapy in The Absence of SHP-1
Mini review · 24 Jun 2021
Chemo 2.0: Programmed Necrosis Agents for Broader and More Effective Cancer Immunotherapy
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Erlinda Maria Gordon”

